- Home
- IDYA
as 12-18-2024 11:38am EST
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.6B | IPO Year: | 2019 |
| Target Price: | $53.67 | AVG Volume (30 days): | 997.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.72 - $47.74 | Next Earning Date: | 11-04-2024 |
| Revenue: | $3,922,000 | Revenue Growth: | -83.30% |
| Revenue Growth (this year): | -79.38% | Revenue Growth (next year): | 251.89% |
Latest IDEAYA Biosciences Inc. News
IDYA Breaking Stock News: Dive into IDYA Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial
PR Newswire
a day ago
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
PR Newswire
2 days ago
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Simply Wall St.
2 days ago
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years
PR Newswire
7 days ago
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
PR Newswire
8 days ago
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
MT Newswires
9 days ago
IDEAYA Biosciences Nominates IDE892 as Development Candidate
PR Newswire
9 days ago
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
Compare IDYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IDYA IDEAYA Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.